论文部分内容阅读
目的:观察经导管肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝细胞肝癌(HCC)的初步疗效和毒性反应。方法:选取病理证实或临床诊断及符合受试标准的中晚期HCC患者17例,行TACE治疗,术后口服索拉非尼,400mg/次,每日2次,每4～6周根据REC IST标准进行肿瘤应答的评价,并记录不良反应的发生情况。结果:近期疗效无部分缓解病例,进行独立评价的12例患者中,共10例获得疾病稳定。观察时间内的患者总体存活率为76.5%。17例患者中不良反应发生率为82.3%,经相应处理后绝大多数获得明显缓解。结论:TACE联合索拉非尼治疗中晚期HCC患者有可能获得较长的生存时间和疾病稳定状态,安全性好,值得扩大病例进一步观察。
Objective: To observe the preliminary efficacy and toxicity of transcatheter hepatic arterial chemoembolization (TACE) and sorafenib in the treatment of advanced hepatocellular carcinoma (HCC). Methods: Twenty-seven patients with pathologically confirmed or clinically diagnosed HCC were enrolled in this study. TACE was performed in patients with advanced HCC. After oral administration of sorafenib, 400 mg twice daily and every 4-6 weeks according to REC IST Standard tumor response evaluation, and record the occurrence of adverse reactions. Results: In the short term, there was no partial remission. Of the 12 patients who were independently evaluated, 10 were stable. The overall survival rate of patients during the observation period was 76.5%. The incidence of adverse reactions in 17 patients was 82.3%, and the vast majority of them were relieved after the corresponding treatment. Conclusion: TACE combined with sorafenib in patients with advanced HCC may have longer survival time and stable disease, which is safe and worthy of further observation.